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Intermittent screening and 
treatment with dihydroartemisinin-
piperaquine and intermittent 
preventive therapy with 
sulfadoxine-pyrimethamine have 
similar effects on malaria antibody 
in pregnant Malawian women
Andrew teo1,2, Louise M. Randall1,3, Mwayiwawo Madanitsa4,5, Victor Mwapasa  4,  
Linda Kalilani phiri4, Carole Khairallah5, Christelle Buffet1,3, Amalia Karahalios6, 
David L. Narum2, Feiko O. Ter Kuile7 & Stephen J. Rogerson  1,3
In a randomised trial comparing intermittent screening and treatment (Ist) with dihydroartemisinin-
piperaquine (Dp) and intermittent preventive therapy against malaria in pregnancy (Ipt) with 
sulfadoxine-pyrimethamine (SP) in Malawi, the impacts of IST-DP and IPT-SP on the development 
and maintenance of malaria antibody immunity were compared. Pregnant Malawian women were 
randomised to receive IST-DP or IPT-SP. In a nested study, paired enrolment and delivery plasma 
samples from 681 women were assayed for antibodies against recombinant antigens and for IgG and 
opsonising antibodies to antigens found on infected erythrocytes (IEs). At delivery, antibody responses 
did not differ between study arms. Between enrolment and delivery, antibodies to recombinant 
antigens decreased, whereas antibodies to IEs including opsonising antibodies remained stable. 
Overall, changes in antibody responses over pregnancy did not differ by treatment arm. Stratifying 
by gravidity, antibody to schizont extract decreased more in multigravidae receiving IST-DP than 
IPT-SP. There was minimal impact of treatment arm on the development and maintenance of malaria 
immunity. While antibodies to recombinant antigens declined between enrolment and delivery, 
antibodies directed against IEs tended to be more stable, suggesting longer-lasting protection.
Clinical trial registration: Pa n African Clinical Trials Registry (PACTR201103000280319) 14/03/2011. 
URL: http://www.isrctn.com/ISRCTN69800930.
Malaria in pregnancy (MiP) increases the risk of mortality and morbidity in pregnant women and their infants1. 
A first-time pregnant mother is at the highest risk, but intermittent preventive therapy during pregnancy (IPT) 
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can reduce the impact of MiP. Sulfadoxine-pyrimethamine (SP) is the only drug recommended for IPT, but emer-
gence of resistance threatens ongoing efficacy2,3.
One alternative strategy for malaria prevention is intermittent screening and treatment (IST), in which a rapid 
diagnostic test (RDT) is performed at each scheduled antenatal visit, and if the RDT is positive, participants are 
given effective antimalarial drug(s).
In pregnancy, Plasmodium falciparum infected erythrocytes (IEs) sequester in the placenta, and these IEs 
express VAR2CSA, a unique variant surface antigen (VSA) that binds to the placental receptor chondroitin sulfate 
A (CSA)4. Antibody targeting placental-binding IEs is acquired over successive pregnancies, and is associated 
with protection against MiP and its consequences5,6. Most studies of antibody responses have used samples col-
lected during the last trimester or at delivery, but pregnant women begin to acquire antibody to placental-binding 
IEs early in first pregnancy7,8, and the use of IPT-SP has been shown to slow acquisition of such immunity9. IST 
relies on RDT-based detection of infection and will not detect placental-sequestered parasites or submicroscopic 
infections, thus potentially exposing pregnant women to longer periods of parasitaemia than IPT. Whether this 
affects the development of pregnancy-specific immunity, or the maintenance of malaria immunity more gen-
erally, is unknown, but studies mainly in non-pregnant hosts show that antibody is important in clearance of 
malaria infection, including infections with drug-resistant parasites10,11.
Using samples from 681 pregnant Malawian women participating in a clinical trial of IPT-SP compared to IST 
with dihydroartemisinin-piperaquine (DP)12, we evaluated the impact of IST or IPT on acquisition and main-
tenance of malarial immunity. We compared antibody responses at study enrolment and delivery and change in 
antibody responses from enrolment to delivery by treatment arm, and evaluated the effect of malaria infection 
during pregnancy on antibody measurements.
Results
Participants’ characteristics. At enrolment, participants’ characteristics were similar between women 
receiving IPT-SP (N = 333) and IST-DP (N = 348), except that women receiving IPT-SP were slightly heavier 
(mean; standard deviation = 54.9 kg; 7.3) than those receiving IST-DP (53.0 kg; 6.8), Table 1. During follow-up, 
more women in the IPT-SP arm experienced febrile episodes (8.2% vs 1.1%, for IPT-SP and IST-DP, respectively), 
and at delivery, there were fewer LBW deliveries in the IPT-SP arm (10.5% vs 15.7% for IPT-SP and IST-DP, 
respectively; Table 1).
Antibody responses to P. falciparum antigens at delivery. Median antibody responses to schizont 
extract, recombinant merozoite antigens and median total antibodies or opsonising IgG to endothelial-binding 
and placental-binding IEs did not differ by treatment arm at delivery (Table 2 and Fig. 1). However, other factors 
were associated with some of the antibodies measured. Multigravidae had higher antibody responses to several 
pregnancy-specific antigens than women in first or second pregnancy [3D7-DBL5: coeff = 1.4 (95% CI 1.1, 1.7), 
P = 0.002; IgG to placental-binding CS2 IEs, coeff = 1.3 (1.1, 1.5), P = 0.01; opsonising IgG to CS2 IEs, coeff = 1.4 
(1.3, 1.5), P < 0.0001]. P. falciparum infection at enrolment was associated with slightly higher IgG responses 
to MSP3 [coeff = 1.2 (1.0, 1.5), P = 0.04], and opsonising IgG to endothelial-binding IEs [coeff = 1.1 (1.0, 1.2), 
P = 0.03], but associated with lower total IgG responses to placental-binding IEs [coeff = 0.7 (0.5, 1.0), P = 0.02]. 
Malarial antibodies also differed by study site. Compared to women from Madziabango, women from Mpemba 
had lower IgG responses to 3D7-DBL5 [coeff = 0.5 (0.3, 0.9), P = 0.02], and in Chikwawa, they had lower IgG 
responses to PfRh2, coeff = 0.2 (0.2, 0.4), P < 0.0001; MSP3, coeff = 0.6 (0.5,0.9), P = 0.03; 3D7-DBL5 coeff = 0.2 
(0.1, 0.4), P < 0.0001; and opsonising antibody to endothelial-binding IEs coeff = 0.8 (0.7, 1.0), P = 0.04, consist-
ent with the higher parasite prevalence reported in Madziabango in the parent trial12. Importantly, there was no 
evidence of an interaction between intervention arm and study site in their effects on malarial antibodies.
Changes in antibody responses to P. falciparum antigens during pregnancy. Median antibody 
responses to recombinant antigens and schizont extract declined over the course of pregnancy in both treatment 
arms (Fig. S1), but there were no differences in responses between treatment arms at either time point.
When we examined antibody to IEs, there was an increase in total IgG antibody to endothelial-binding IEs 
in the IPT-SP arm at delivery, but this association was absent for placental-binding IEs and in the IST-DP arm 
to both parasite strains, Fig. S1B. The median opsonising IgG responses did not vary between enrolment and 
delivery in either arm, Fig. S1C. There were no other differences in the antibody responses to IEs VSA at either 
time point.
Changes in individual antibody responses during pregnancy between treatment groups. 
Antibody responses in the IST-DP group varied more between enrolment and delivery than those in the IPT-SP 
group. In particular, in multigravid women antibody responses to schizont extract increased substantially over 
pregnancy, [mean = 14.3 (6.2, 22.5) P < 0.001] (Fig. 2).
Modification of changes in antibody responses from enrolment to delivery by infection. Women were 
stratified according to presence or absence of P. falciparum at enrolment (by microscopy and/or PCR) in each 
treatment group. The most striking changes in antibody from enrolment to delivery were seen in women infected 
at enrolment, and for responses to recombinant antigens and schizont extract, Fig. 3. Antibody to DBL5, MSP2 
and schizont extract declined in both treatment arms, while antibody to MSP3 and PfRh2 declined only in the 
IPT-SP arm. In the IPT-SP group, there were modest increases in antibody to VSA of both CS2 and E8B IEs 
among uninfected women, and in the IST-DP group, there was an increase in opsonising IgG antibody to CS2 
IEs. In contrast, antibody to schizont extract decreased from enrolment to delivery in both groups regardless of 
infection status at enrolment. Other responses did not change, Fig. 3.
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When stratified based on infection status at delivery (by histology and/or microscopy), infected women in 
the IST-DP group tended to have increases in antibody to VSA of CS2 IEs, Fig. 4. Interestingly, among women 
with malaria at delivery, opsonising IgG to CS2 IE and antibody to schizont extract declined from enrolment to 
delivery in women who received IPT-SP, and among women receiving IST-DP, there were declines in antibody 
responses to DBL5 and MSP2 from enrolment to delivery, Fig. 4.
Discussion
In the context of a randomised trial of IST-DP compared to IPT-SP in pregnant Malawian women, we investi-
gated the effect of each treatment on antibody immunity to malaria, and determined whether IST-DP altered the 
development and maintenance of pregnancy-specific antibody immunity when compared to IPT-SP. Antibodies 
to recombinant antigens, but not functional antibodies, declined during pregnancy in both arms. There was no 
evidence of a differential impact on malarial humoral immunity between treatment arms, but when participants 
were stratified by gravidity, multigravid women receiving IST-DP had increases in antibody to schizont extract 
from enrolment to delivery, possibly due to increased exposure to low-density malaria infections that were not 
detected by RDT during scheduled antenatal visits.
At delivery, there were no differences in levels of antibody to schizont extract and recombinant antigens or 
to antigens expressed on IEs between treatment arms. The lack of broad differences between groups may in part 
reflect the relatively low incidence of malaria infections and short duration of follow up in this well-protected 
group of women.
In the absence of effective malaria prevention, pregnant women develop increasing levels of pregnancy-specific 
immunity between antenatal booking and delivery, with the greatest increases seen in first pregnancies7,13. 
By contrast, in the present study antibodies to schizont extract, merozoite antigens and to VAR2CSA-DBL5 
declined over the course of pregnancy, and total IgGs and opsonising antibodies to VSA of placental-binding 
and endothelial-binding IEs were generally stable, largely consistent with recent studies in Papua New Guinea, 
At enrolment
Intermittent preventive 
treatment (SP) (N = 333)
Intermittent screening and 
treatment (DP) (N = 348)
Study site
Madziabango 103 (30.9) 117 (33.6)
Mpemba 110 (33.0) 112 (32.2)
Chikwawa 120 (36.0) 119 (34.2)
Age, years 20 (18–23) 20 (18–22)
Gravidity
Gravida 1 165 (49.5) 161 (41.9)
Gravida 2 117 (35.1) 118 (33.9)
Gravida 3+ 51 (15.3) 68 (19.5)
Weight, kg 54.7 (7.3) 53.7 (6.8)
Height, cm (SD) 154.1 (4.9) 153.5 (4.7)
BMI, kg/m2 (SD) 24.0 (2.9) 22.8 (2.8)
Haemoglobin, g/dl (SD) 10.7 (1.4) 10.7 (1.4)
Anaemia at enrolment, Hb < 11.0 g/dl 185 (55.6) 184 (52.9)
Parasitemia (light microscopy) 63/329 (19.1) 62/341 (17.9)
Parasitemia (qPCR) 147/327 (45.0) 177/343 (51.6)
Bed net use at enrolment 68 (20.4) 73 (21.0)
IRS last 12 months 40/329 (12.2) 37/346 (10.7)
Socio-economic status
Low 108 (32.5) 101 (29.1)
Medium 120 (35.8) 134 (38.3)
High 105 (31.6) 112 (32.6)
At delivery
Haemoglobin, g/dL (SD) 11.7 (1.5) 11.8 (1.6)
Anaemia at delivery 98/326 (30.0) 84/336 (25.0)
Placental malaria on histology bInfectedb, n/N (%) 109/300 (36.3) 122/324 (37.6)
Peripheral parasitemiaa a(qPCR) 60/317 (18.9) 79/337 (23.4)
Newborn sex male, 181/326 (55.6) 166/336 (49.4)
Birth weight, g (SD) 2897 (447) 2863 (406)
Low birth weight <2500 g (%) 34/323 (10.5) 52/332 (15.7)
Table 1. Study population characteristics at enrolment and delivery in IPT-SP and IST-DP arms. NOTE. 
Data presented as n (%) or mean (SD), unless otherwise indicated. DP, dihydroartemisinin-piperaquine; 
SP, sulfadoxine-pyrimethamine; SD, standard deviation; BMI, body mass index; Hb, haemoglobin; qPCR, 
quantitative polymerase chain reaction; IRS, indoor residual spraying. aParasitemia based on microscopy and 
qPCR. bInfected placentas classified based on histology reading of active or chronic infection.
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Benin and Malawi5,14,15. The exception to this was an increase in total IgG responses to endothelial-binding IEs in 
the IPT-SP group, which may indicate that placental-binding isolates are not the only variants infecting pregnant 
women16. The lack of change in antibody to IEs suggests that haemodilution associated with pregnancy does 
not explain the changes in antibody responses to recombinant merozoite antigens, VAR2CSA-DBL5 or schizont 
extract. Instead, their half-lives may be shorter than those for antibodies to VSA17. Our findings, together with 
previous studies, highlight the importance of studying functional antibodies to malaria18, potentially including 
measures of antibody avidity and binding-inhibition antibodies against placental-binding IEs19–21. This will allow 
better understanding of the impact of intervention on the development of protective antibodies.
VSAs such as Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) are important targets for 
opsonising phagocytosis and binding-inhibition21–23. Opsonising antibody targets parasite antigens in their natu-
ral configuration on the IEs surface, but recombinant VAR2CSA antigens may not be presented in the same way. 
The declines over pregnancy we observed in levels of VAR2CSA-DBL5 antibodies are similar to those observed 
with most domains of VAR2CSA in Benin5, the exceptions being full-length VAR2CSA and VAR2CSA-DBL6, 
which both increased over pregnancy. VAR2CSA-DBL5, together with VAR2CSA-DBL2 and VAR2CSA-DBL3, is 
reported to be an important target of opsonising antibodies23, but the differences in dynamics of these responses 
over pregnancy and responses to intact IEs suggests that IgG assayed by ELISAs may not be a good correlate of 
more functional antibodies.
When results were stratified according to presence of malaria infection at delivery, women in the IST arm who 
had malaria infection tended to have higher IgG responses to placental-binding IEs. IST is not presently endorsed 
by the World Health Organization24, in part because current RDTs miss too many low-density infections. Our 
observations of a modest decrease in IgG antibody to CS2 IEs at delivery in infected women receiving IPT-SP and 
similar modest increase in opsonising antibody to CS2 IEs in IST-DP recipients are consistent with this, suggest-
ing boosting of antibody responses by infections in women receiving IST but not IPT.
After adjusting for covariates, treatment arms did not influence acquisition and/or maintenance of 
malarial antibodies over pregnancy. As expected, higher gravidity was associated with increased levels of 
pregnancy-associated antibodies, indicating more exposure to placental-binding parasites during previous preg-
nancies. Of note, women who were infected at study entry had higher antibody responses to non-pregnancy 
related antigens, but had lower antibody responses to placental-binding antigens. An earlier study in Benin 
demonstrated persistent P. falciparum infection in nulligravidae, and during the first trimester, these women 
experienced an increased risk of parasitaemia. Importantly, the administration of IPT decreased the risk of para-
sitaemia during pregnancy25. This possibly suggests infection with endothelial-binding parasites that resulted in 
Variables
IgG schizont 
extract IgG PfRh2 IgG MSP2 IgG MSP3 IgG 3D7-DBL5
Total IgG to 
endothelial-
binding IE
Opsonising Ab 
to endothelial-
binding IE
Total IgG to 
placental-
binding IE
Opsonising Ab to 
placental-binding 
IE
Coeff 
(95%Cl) P
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
Coeff 
(95%Cl) p
IPT-SP Ref Ref Ref Ref Ref Ref Ref Ref Ref
IST-DP 1.1 (0.8–1.5) 0.5
1.1 
(0.8–1.7) 0.5
0.9 
(0.7–1.2) 0.5
1.1 
(0.8–1.6) 0.5
1.0 
(−0.6–1.7) 0.9
0.9 
(0.6–1.4) 0.7
1.0 
(0.8–1.1) 0.7
1.1 
(0.7–1.7) 0.6
1.1 
(0.9–1.4) 0.3
Gravidity
Paucigravid Ref Ref Ref Ref Ref Ref Ref Ref Ref
Multigravid 0.9 (0.9–1.1) 0.5
1.1 
(0.9–1.3) 0.2
1.1 
(0.9–1.2) 0.4
1.1 
(1.0–1.3) 0.1
1.4 
(1.1–1.7) 0.002
1.1 
(1.0–1.4) 0.2
1.0 
(0.9–1.1) 0.9
1.3 
(1.1–1.5) 0.01
1.4 
(1.3–1.5) <0.0001
P. falciparum at enrolmenta
No Ref Ref Ref Ref Ref Ref Ref Ref Ref
Yes 1.1 (1.0–1.3) 0.08
1.2 
(0.9–1.5) 0.1
1.1 
(0.9–1.3) 0.4
1.2 
(1.0–1.5) 0.04
1.1 
(0.8–1.4) 0.5
0.8 
(0.6–1.1) 0.2
1.1 
(1.0–1.2) 0.03
0.7 
(0.5–1.0) 0.02
1.0 
(0.9–1.2) 0.5
Study-site
Madziabango Ref Ref Ref Ref Ref Ref Ref Ref Ref
Mpemba 1.0 (0.7–1.4) 1.0
1.0 
(0.6–1.6) 0.9
0.7 
(0.5–1.0) 0.08
1.0 
(0.7–1.6) 0.8
0.5 
(0.3–0.9) 0.02
1.4 
(0.9–2.3) 0.1
1.0 
(0.8–1.2) 0.8
0.7 
(0.4–1.1) 0.1
0.8 
(0.7–1.1) 0.1
Chikwawa 0.9 (0.7–1.2) 0.7
0.2 
(0.2–0.4) <0.0001
0.9 
(0.6–1.2) 0.3
0.6 
(0.5–0.9) 0.03
0.2 
(0.1–0.4) <0.0001
1.4 
(0.9–2.2) 0.1
0.8 
(0.7–1.0) 0.04
0.8 
(0.5–1.3) 0.5
0.5 
(0.6–1.5) 0.1
IST-DPb Study sites
Madziabango Ref Ref Ref Ref Ref Ref Ref Ref Ref
Mpemba 0.7 (0.5–1.1) 0.1
0.8 
(0.4–1.3) 0.3
0.9 
(0.6–1.4) 0.7
0.8 
(0.5–1.3) 0.4
0.9 
(0.5–1.8) 0.8
1.1 
(0.6–2.0) 0.7
1.0 
(0.9–1.3) 0.8
0.8 
(0.4–1.7)
1.1 
(0.8–1.5) 0.5
Chikwawa 0.9 (0.6–1.3) 0.7
0.9 
(0.5–1.5) 0.7
1.0 
(0.7–1.5) 0.9
1.2 
(0.5–1.4) 0.5
1.0 
(0.5–1.8) 0.9
1.3 
(0.7–2.3) 0.5
1.1 
(0.9–1.3) 0.6
0.7 
(0.4–1.4)
0.8 
(0.6–1.1) 0.2
Table 2. Linear regression models of antibodies at delivery (analysed as natural log, and antilogged back 
to antibody units in table), adjusting for confounders and interaction terms. Results presented as ratio of 
geometric means and 95% confidence interval, and P-values. A coefficient between 0–1 implies a decrease of 
antibody levels. aInfection based on blood smears and quantitative polymerase chain reaction; bIST-DP was 
fitted into an interaction model with study-sites.
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boosted antibody responses before placental development, and that anti-malarials administered during second 
trimester effectively cleared parasitaemia resulting in lower exposure to placental-binding IEs. Of the three study 
sites, women in Madziabango tended to have the highest malaria antibody responses, consistent with the highest 
rates of parasitaemia being observed there. Importantly, IST-DP did not modify antibody responses in the dif-
ferent study sites.
Strengths of the study include a large data set of over 600 women whose antibody responses were measured 
to a range of malaria antibody targets twice in pregnancy. Study limitations include high bed net coverage and 
frequent IST-DP or IPT-SP, which may have reduced the incidence and density of malaria infection. Second, SP 
resistance was not determined and parasites were not genotyped, so we are unable to determine whether infec-
tion was due to reinfection or recrudescence. Lastly, we did not have blood specimens during ANC visits to assay 
for the dynamics of antibody responses between each treatment, which could provide further understanding on 
impact of such interventions.
In this study, we have assessed associations for several antibody responses, resulting in a number of tests and 
associated p-values. We chose not to penalise our p-values for the multiple testing, as this is a contentious issue 
in the literature (see for example26) but instead we have presented the effect estimate, 95% confidence interval 
and corresponding p-value for associations of interest and have sought to illustrate comparisons that lead to 
similar trends of potential relevance. The reader should be cautioned against interpreting these results in terms of 
Figure 1. Immunoglobulin G (IgG) antibodies to P. falciparum antigens at delivery according to treatment 
group. White box – Pregnant women receiving IPT-SP, N = 333, grey box – Pregnant women receiving IST-DP, 
N = 348. (A) Levels of IgG to schizont extract and recombinant proteins MSP2, MSP3, PfRH2 and 3D7-
DBL5. (B) IgG responses to variant surface antigens of endothelial-binding and placental-binding infected 
erythrocytes (IEs). (C) Levels of opsonising IgG to variant surface antigens of endothelial-binding and 
placental-binding IEs, presented as percentage of THP-1 cells that have ingested IEs (Phagocytosis, relative to 
positive controls). Data presented in box and whiskers plot box showing median and IQR, and whiskers 10–90 
percentiles with outliers in closed circles. Results are presented as percentage of positive controls.
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statistical significance, and interpret the 95% confidence intervals in terms of the magnitude of the effect and not 
merely on whether or not they cross the null value27.
In conclusion, there was minimal difference in malarial antibody between women receiving IPT-SP and 
IST-DP at delivery, possibly due to low force of infection and high bed net coverage. The decline between enrol-
ment and delivery in antibody measured against several targets by ELISA supports this. Further studies should 
explore whether the decline of antibody responses over pregnancy has an impact on the transfer of maternal 
antibodies to her infant and whether this results in an increase in malaria incidence during infancy. More sensi-
tive diagnostics in the form of regular blood smears and/or better RDTs are required for future evaluation of IST 
and possibly IPT protocols, as the increases in some antibody responses observed here suggest ongoing malaria 
exposure, which may lead to poor pregnancy outcomes.
Materials and Methods
Ethics approval. The study protocol was reviewed and ethical approval was obtained from Research Ethics 
Committees of the Liverpool School of Tropical Medicine, the College of Medicine Research Ethics Committee, 
University of Malawi, and the National Health Sciences Research Committee, Ministry of Health, Malawi. The 
laboratory studies were approved by the Melbourne Health Human Research Ethics Committee, Australia. The 
study was conducted in accordance with Good Clinical Practice guidelines (ICH GCP E6) The trial was registered 
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149, 4.99 (27.27)
110, 2.82 (43.16)
64, -4.84 (33.79)
323, 2.31 (34.77)
156, 16.77 (108.18)
116, 44.91 (418.08)
66, 2.00 (25.03)
338, 23.54 (255.77)
158, 48.67 (516.15)
115, 4.51 (30.35)
66, 6.84 (21.46)
339, 25.54 (353.01)
146, 9.04 (25.35)
110, 6.35 (16.71)
62, 2.23 (23.16)
318, 6.78 (22.35)
154, 0.43 (991.44)
115, 18.35 (55.39)
60, -3.31 (24.67)
329, 6.01 (678.06)
159, 0.12 (20.78)
117, -0.40 (23.52)
67, -4.75 (31.09)
343, -1.00 (24.02)
158, -1.58 (13.99)
114, 0.26 (9.03)
66, -4.15 (20.04)
338, -1.46 (14.08)
158, -4.75 (39.51)
116, 1.28 (49.72)
67, -9.35 (34.76)
341, -3.60 (42.51)
154, -5.85 (31.58)
110, -1.85 (31.36)
64, -3.60 (23.46)
328, -4.07 (30.06)
IST-DP, N, mean
change scores (SD)
154, 3.37 (48.58)
108, 28.20 (156.80)
49, 1.41 (25.78)
311, 11.68 (99.50)
159, 16.71 (70.39)
110, 13.79 (73.94)
49, 8.22 (18.44)
318, 14.39 (66.40)
159, 14.89 (108.29)
113, 1.11 (88.96)
48, 10.56 (17.46)
320, 9.38 (93.12)
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Figure 2. Immunoglobulin G (IgG) antibodies to P. falciparum antigens at delivery according to treatment 
group. Pregnant women receiving IPT-SP, N = 333, Pregnant women receiving IST-DP, N = 348. Mean 
difference compares the change in antibody response from enrolment to delivery between the IST-DP and 
IPT-SP treatment arms after adjusting for antibody response at enrolment.
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with Pan African Clinical Trials Registry (PACTR201103000280319, 14/03/2011). All participants provided 
informed written consent12.
Study sites and participants. Full details of the trial were recently published12; in brief, this study 
was conducted in Chikwawa and Blantyre Districts, Malawi. Pregnant women between 16–28 weeks’ gesta-
tion and free from chronic illness were randomly assigned to receive IPT-SP or IST-DP, and all were given an 
insecticide-treated net (ITN). At each of 3 or 4 scheduled antenatal visits, women in the IPT-SP group were given 
1,500 mg sulfadoxine and 75 mg pyrimethamine as 3 tablets. Women in the IST-DP group had an RDT performed 
and if this was positive, received a standard 3-day course of DP by body weight. All treatments in both arms 
were directly observed. At delivery, placental biopsies were collected, and placental malaria was defined as active 
infection at delivery by histology. Plasma samples were collected at enrolment and at delivery, and paired samples 
from 333 participants receiving IPT-SP and 348 receiving IST-DP were assayed for antibody responses against P. 
falciparum antigens. All available paired samples were tested.
Parasites and cell cultures. Placental-binding (CS2) and endothelial-binding (E8B) IEs were cultured as 
previously described, and were used to measure antibodies to the IEs surface28,29.
THP-1 monocyte-like cells were cultured28 and used to estimate opsonising antibodies.
Assay of IgG to recombinant antigens and schizont extract. Plasma samples were assayed by 
enzyme-linked immunosorbent assay (ELISA) as previously described30. In brief, microtitre plates were coated 
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Figure 3. Change in immunoglobulin G (IgG) antibodies to P. falciparum antigens from enrolment to delivery 
stratified by infection status at enrolment and by treatment arm. Median difference compares the change in 
antibody response from enrolment to delivery between the IPT-SP and IST-DP treatment arms.
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with 50 µL of individual targets diluted in phosphate buffered saline (PBS) at the following concentrations: 
schizont extract from CS2 IEs 1/2000; MSP2 from FC27 0.5 µg/ml; MSP3 from 3D7 full ectodomain 2 µg/ml; 
PfRh2 (construct PfRh2-2030 from 3D7) 0.5 µg/ml; and VAR2CSA-DBL531 from 3D7 0.5 µg/ml. Plasma was 
added in duplicate (1:1000). A standard curve generated from serial dilution of the positive controls (composed 
of pooled plasma from 44 pregnant women with high antibody responses to CS2 IEs), was used to convert opti-
cal density (OD) into antibody level represented in arbitrary units. In each plate, plasmas from six non-exposed 
pregnant women from Melbourne were included as negative controls.
Total IgG antibody to variant surface antigens of infected erythrocytes. In brief, test plasma was 
incubated with placental-binding or endothelial-binding IEs at 4–8% parasitaemia (1:20) in duplicate, followed 
by incubation with rabbit anti-human IgG (1:100, Dako), and with AlexaFluor 647 donkey anti-rabbit (1:500, 
Invitrogen) supplemented with 10 µg/ml ethidium bromide (EtBr), in the dark. The cells were re-suspended in 2% 
paraformaldehyde (PFA) and analysed with flow cytometry29. The positive pooled plasma and negative controls 
used in ELISAs were run on each plate, and antibody to IEs was expressed as relative geometric mean fluorescence 
intensity (MFI), represented as a percentage of the MFI of the positive pooled plasma, after subtraction of the 
negative controls.
Measurement of opsonising antibody against infected erythrocytes. In brief, purified trophozoite- 
stage IEs stained with 10 µg/ml EtBr were re-suspended at 1.67 × 107/ml and opsonised with test samples (1:10). 
Opsonised IEs were then aliquoted in duplicates and incubated with THP-1 cells in a 5% CO2 humidified incu-
bator at 37 °C. Phagocytosis was arrested and unphagocytosed IEs were lysed before being re-suspended in 2% 
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Figure 4. Change in immunoglobulin G (IgG) antibodies to P. falciparum antigens from enrolment to delivery 
stratified by infection status at delivery and by treatment arm. Median difference compares the change in 
antibody response from enrolment to delivery between the IPT-SP and IST-DP treatment arms.
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PFA. Test samples were then analysed with flow cytometry and opsonising antibody was detected as proportion 
of THP-1 cells positive for EtBr, and expressed as a percentage of positive control28.
Data analysis. Non-parametric continuous variables were analysed using Mann-Whitney U test (Fig. 1) and 
categorical variables were tested using Chi-squared test (Table 1).
To compare antibody responses at delivery between the two treatment groups (i.e. IST-DP vs IPT-SP), we 
fitted separate linear regression models for each of the antibody measures. Because the antibody responses were 
non-normally distributed, the log-transformed antibody responses at delivery were the outcome variables and 
intervention was the exposure of interest (i.e. IST-DP vs IPT-SP). We assessed if site of intervention at enrolment, 
gravidity, or presence of P. falciparum parasitaemia at enrolment modified the association between intervention 
and each antibody response at delivery by fitting separate interaction terms and testing the interactions with 
likelihood ratio tests. Our final models included the interaction of intervention (IST-DP vs IPT-SP) with study 
site, which was found to modify the association between intervention and antibody response (based on a p-value 
of <0.05) and also adjusted for gravidity, and the presence of P. falciparum parasitaemia at enrolment (Table 2). 
To compare antibody responses at enrolment, we fitted linear regression models (as above) but antibody levels at 
enrolment were now the outcome variable.
To compare change in antibody responses between enrolment and delivery, we fitted a linear regression 
model. The outcome variable was the change in antibody response between enrolment and delivery in each treat-
ment group (note that this change was determined for women who were infected or uninfected at enrolment or 
at delivery); treatment (i.e. IST-DP vs IPT-SP) was the exposure of interest and we further adjusted for antibody 
response at enrolment (Fig. 2; presented overall and by gravidity). To assess how presence of malaria infection 
at enrolment or delivery modified the change in antibody responses during pregnancy, we presented the results 
of the quantile regression models by infection status at enrolment (Fig. 3) and at delivery (Fig. 4). To obtain the 
corresponding standard errors and 95% confidence intervals for the quantile regression models (Figs 2–4), we 
performed 200 bootstrap replications.
Data were analysed using Stata v14 (StataCorp).
Data Availability
The datasets generated and/or analysed in the current study are available from the corresponding author by 
written request.
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